Having trouble accessing articles? Reset your cache.

Investors reward Fate for off-the-shelf NK data at ASH

Fate’s 41% gain following presentations at ASH solidifies its iPS cell-derived NK platform’s status as the company’s center of gravity. The company is advancing a series of increasingly complex off-the-shelf NK cell therapies, with a thrice-modified candidate slated to enter the clinic early next year.

Fate Therapeutics Inc. (NASDAQ:FATE) gained $5.65 to

Read the full 511 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers